According to Pluo Pharmaceutical's announcement, the company and the related party Hengdian Co., Ltd. provided financial support to its subsidiary Zhejiang Anteyutai Biotechnology Co., Ltd. according to the investment ratio. Of these, the company invested 255 million yuan and Hengdian Co., Ltd. invested 245 million yuan. The funds were provided in batches as needed. The funding period was no more than 3 years, and the annualized interest rate was 3%. This transaction constitutes a related transaction. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting. After this funding, the total balance of the company's financial support was 255 million yuan, accounting for 3.88% of the most recent audited net assets, with no overdue financial support.

According to Pluo Pharmaceutical's announcement, the company and the related party Hengdian Co., Ltd. provided financial support to its subsidiary Zhejiang Anteyutai Biotechnology Co., Ltd. according to the investment ratio. Of these, the company invested 255 million yuan and Hengdian Co., Ltd. invested 245 million yuan. The funds were provided in batches as needed. The funding period was no more than 3 years, and the annualized interest rate was 3%. This transaction constitutes a related transaction. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting. After this funding, the total balance of the company's financial support was 255 million yuan, accounting for 3.88% of the most recent audited net assets, with no overdue financial support.